CERo Therapeutics
OTC: CEROSan Francisco, US · Founded 2016 · Delaware corporation · 1 known investors
CERo Therapeutics develops engineered T cell immunotherapies designed to treat cancer by combining innate and adaptive immune mechanisms; the company is conducting clinical trials of CER-1236, an autologous T cell product targeting TIM-4 ligand, in acute myeloid leukemia and other hematological malignancies, with planned expansion into solid tumors including non-small cell lung cancer and ovarian cancer.
Founders & leadership
CERo Therapeutics was founded in 2016 by Daniel Mark Corey.
Investors · 1
Funding
SEC filings, press & company announcements$44.6M disclosed across 2 of 3 rounds · 2017–2026
▶$43.2MraisedNov 2019 · 31 investors · OtherRule 506(b)
- Stan RiddellDirector
- Heather TurnerDirector
- Daniel Mark CoreyExecutive Officer, Director, Promoter
- Stuart SloanDirector
- Lawrence CoreyExecutive Officer, Promoter
- Jordan CoreyExecutive Officer, Promoter
- Offering amount
- $43.2M
- Amount sold
- $43.2M
- First sale
- Nov 2019
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
▶$1.4MraisedMar 2017 · 7 investors · OtherRule 506(b)
- Lawrence CoreyExecutive Officer, Director
- Jordan Thomas CoreyExecutive Officer
- Daniel Mark CoreyDirector
- Offering amount
- $2.5M
- Amount sold
- $1.4M
- First sale
- Feb 2017
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed eventsSource: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
In the news
Frequently asked questions
- What does CERo Therapeutics do?
- CERo Therapeutics develops engineered T cell immunotherapies designed to treat cancer by combining innate and adaptive immune mechanisms; the company is conducting clinical trials of CER-1236, an autologous T cell product targeting TIM-4 ligand, in acute myeloid leukemia and other hematological malignancies, with planned expansion into solid tumors including non-small cell lung cancer and ovarian cancer.
- Who founded CERo Therapeutics?
- CERo Therapeutics was founded by Daniel Mark Corey in 2016.
- Who are CERo Therapeutics's investors?
- CERo Therapeutics's investors include Keystone.
- How much funding has CERo Therapeutics raised?
- CERo Therapeutics has disclosed $44.6M raised across 2 of its 3 known rounds.
- Where is CERo Therapeutics headquartered?
- CERo Therapeutics is headquartered in San Francisco, US.